Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Double-Blind, Placebo-Controlled Study of Caripazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder

Next Previous
Search
Trial Profile

A Double-Blind, Placebo-Controlled Study of Caripazine (RGH-188) As Adjunctive Therapy In Major Depressive Disorder

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cariprazine (Primary) ; Citalopram; Duloxetine; Escitalopram; Sertraline; Venlafaxine
  • Indications Major depressive disorder
  • Focus Therapeutic Use
  • Sponsors Forest Laboratories

Most Recent Events

  • 24 Jul 2018 Of 502 patients enrolled in the open-label period, 403 completed treatment and 172 were classified as responders. Of the 231 non responders who began double-blind treatment, according to results published in the International Clinical Psychopharmacology.
  • 24 Jul 2018 Primary endpoint (Montgomery-Asberg Depression Rating Scale(MADRS) changes (Assessed at week 16) has not been met, according to results published in the International Clinical Psychopharmacology.
  • 24 Jul 2018 Results (n=502) published in the International Clinical Psychopharmacology.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top